TARS
Tarsus Pharmaceuticals, Inc.
Next earnings Aug 4, 2026 · consensus $-0.26 EPS, $171M rev
Last earnings -0.4% on 2026-05-06
$62.92
▼ -2.21%$62.92▲ +54.98%
over 1Y
L $38.82EODHDH $82.51
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-2.2%
1W-1.0%
1M+4.8%
3M-5.0%
YTD-22.1%
1Y+55.0%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 15 analysts
Strong Buy
Revenue grew 146.7% YoY; but unprofitable (net margin -14.7%).
Revenue (FY2025) $451M · FY2025
Tarsus Pharmaceuticals, Inc. shows $451M in FY2025 revenue (+146.7% YoY), a -14.7% net margin, and -19.3% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $57.0M | $25.8M | $17.4M | $183M | $451M |
| Gross profit | — | — | — | — | — |
| Operating income | -$12.2M | -$62.7M | -$143M | -$121M | -$71.0M |
| Net income | -$13.8M | -$62.1M | -$136M | -$116M | -$66.4M |
| Diluted EPS | -$0.67 | -$2.52 | -$4.62 | -$3.07 | -$1.59 |
| Net margin | -24.2% | -240.5% | -778.9% | -63.2% | -14.7% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$2.57B
EV / EBITDA—
EV / Sales5.7
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-2.5%
FCF yield-0.8%
Quality & risk
ROIC (est.)-13.5%
Free cash flow-$22.3M
Total debt$72.4M
Net cash$111M
Altman Z-Score7.50 safe
Piotroski F-Score4/8
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+10.9%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗4Period ending 2026-06-172026-06-22open ↗4Period ending 2026-06-152026-06-17open ↗4Period ending 2026-06-152026-06-17open ↗4Period ending 2026-06-152026-06-17open ↗144Filing2026-06-17open ↗144Filing2026-06-16open ↗4Period ending 2026-06-122026-06-16open ↗4Period ending 2026-06-122026-06-16open ↗4Period ending 2026-06-122026-06-16open ↗4Period ending 2026-06-122026-06-16open ↗4Period ending 2026-06-122026-06-16open ↗4Period ending 2026-06-122026-06-16open ↗
Frequently asked
- Is Tarsus Pharmaceuticals, Inc. (TARS) a buy?
- TARS currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 146.7% YoY; but unprofitable (net margin -14.7%).
- What is Tarsus Pharmaceuticals, Inc.'s quality score?
- TARS scores 56.17647058823529/100 (grade C) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001819790, latest 10-Q filed 2026-05-06) · EODHD · as of 6/26/2026, 6:40:36 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.